Back to today’s briefing

Story perspectives

New Therapy Boosts Survival for Breast Cancer Patients

6/1/2025

33 2

Summary

Therapy Revolutionizes Breast Cancer

A groundbreaking therapy featuring inavolisib, palbociclib, and fulvestrant is making waves for patients battling PIK3CA-mutated HR+, HER2- breast cancer. Unveiled at the 2025 ASCO meeting, the INAVO120 study revealed a remarkable seven-month boost in overall survival and a 17.2-month delay in disease progression, paving the way for a new standard of care in the UK.

Summary

Trodelvy Advances Cancer Treatment

Gilead Sciences’ Trodelvy emerges as a beacon of hope for metastatic triple-negative breast cancer (TNBC), offering a remarkable boost in progression-free survival over traditional chemotherapy. Anticipation builds as the phase 3 Ascent-04 trial results are set to be unveiled at the 2025 ASCO meeting. Meanwhile, Kelun-Biotech's sacituzumab tirumotecan enters the fray, boasting an impressive 70.7% response rate in early trials.

1 of 2

Therapy Revolutionizes Breast Cancer

A groundbreaking therapy featuring inavolisib, palbociclib, and fulvestrant is making waves for patients battling PIK3CA-mutated HR+, HER2- breast cancer. Unveiled at the 2025 ASCO meeting, the INAVO120 study revealed a remarkable seven-month boost in overall survival and a 17.2-month delay in disease progression, paving the way for a new standard of care in the UK.

1 / 2